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NPHS2 mutations are a common cause of childhood steroid resistant nephrotic syndrome 
(SRNS). APOL1 variants are strongly associated with focal segmental glomerulosclerosis 
(FSGS) in African Americans. In South Africa, SRNS is more frequent among Black children 
compared to Indian children. We investigated whether NPHS2 and APOL1 variants contributed 
to this disparity.  
Methods 
Indian and Black children with Nephrotic Syndrome (NS) from KwaZulu-Natal Province, South 
Africa were enrolled; only SRNS children underwent kidney biopsy. The 64 NS cases and 104 
controls were sequenced for NPHS2 and genotyped for APOL1 risk alleles. A replication group 
comprised 20 Black SRNS cases with FSGS and 18 controls. Haplotype and coalescence 
analyses was used to determine relatedness among the children and to age the mutation. 
Findings 
58% (19/33) of Indian and 97% (30/31) of Black children with NS were steroid resistant (SR) (p 
= 0.0002).   8/30 (26.7%) of all SRNS Black children were homozygous for NPHS2 V260E and 
had FSGS. V260E homozygosity was replicated in 6/20 (30%) of Black children with SR-FSGS. 
V260E was not observed in Indian cases or controls; however, one Black control was 
heterozygous for V260E (minor allele freq. ~0·07%). Children homozygous for V260E 
developed SRNS at an earlier age than non-carriers (median 34 vs. 78 months, p=0·009), and 
none achieved either partial or complete remission (0% vs. 47%, p=0·002) even after intensive 





Sporadic SRNS among unrelated Black children is partially explained by homozygosity for the 
V260E pathogenic mutation, present in 26.7% of those with SRNS and 32% with SR-FSGS 
histology, which is not due to cryptic consanguinity among affected children. Genotyping a 
single mutation in children of Zulu ancestry with NS will identify those with SR-FSGS making it 
possible to avoid kidney biopsy and ineffective steroid or additional intensive 
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1.1  The Human Kidney 
 
Figure 1.1 The Urinary System (Adapted from http://www.faqs.org/health/Body-by-Design-V2/The  
Urinary-System-Design-parts-of-the-urinary- system.html 26/10/2016 at 12.33pm). 
The kidney is situated below the diaphragm and posterior to the liver and the spleen.  It is 
located at the rear wall of the abdominal cavity, just above the waistline (Figure 1.1).  Grossly, 
the kidneys are bean-shaped structures and weigh about 150 grams in the male and about 135 
grams in the female. In an adult they are typically 10-12 cm in length, 5-7 cm in width, and 2-3 
cm in thickness (Messing EM. (2007)  In: Wein AJ (editor-in-chief) and LR 2007).  In a term new-
born the kidney measures 4–5cm  and it is smaller in preterm babies.   
The kidneys serve important functions, including filtration and excretion of metabolic waste 
products (urea and ammonium); regulation of necessary electrolytes, fluid, and acid-base 
balance; and stimulation of red blood cell production. As the kidneys filter blood, they create 
urine, which collects in the kidneys' pelvis - funnel-shaped structures that drain down tubes 
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called ureters to the bladder. They also serve to regulate blood pressure via the renin-
angiotensin-aldosterone system, controlling reabsorption of water and maintaining intravascular 
volume. The kidneys also reabsorb glucose and amino acids and have hormonal functions via 
erythropoietin, calcitriol, and vitamin D activation. 
 
1.1.1 Structure of the Kidney 
1.1.1.1 Cortex and the Medulla 
The kidney is divided into the cortex and medulla. Two layers form them internally. The outer 
layer is the Cortex that contains:  
• Glomeruli  
• Proximal Tubules  
• Cortical Portions of Loop of Henle  
• Distal Tubules  




The inner layer or Medulla is comprised of Renal Pyramids. The pyramids contain:  
• Medullary portions of the Loops of Henle  
• Medullary Portions of the Collecting Ducts  
 
1.2 Functional renal unit 
The multiple pyramids taper and join forming a minor calyx. Several combined make a major 






The functional renal unit, the nephron has five parts namely:  
 The glomerulus, which is the blood kidney interface, plasma is filtered from 
capillaries into the Bowman’s capsule.  
 The proximal convoluted tubule, which reabsorbs most of the filtered load, including 
nutrients and electrolytes.  
 The loop of Henle, which, depending on its length, concentrates urine by increasing 
the osmolality of surrounding tissue and filtrate.  
 The distal convoluted tubule, which reabsorbs water and sodium depending on 
needs. 
 The collecting system, which collects urine for excretion.  There are two types of 
nephrons, those localized to the cortex, and those extending into the medulla. The 
latter are characterized by long loops of Henle, and are more metabolically active. 
1.2.1 Nephrons 
Each kidney contains around a million units called nephrons, each of which is a microscopic 
filter for blood. The nephron, the functional unit of the kidney selectively filters molecules from 
blood plasma to form a filtrate (Figure 1.2); (Zuo 2006).  The nephron has two main parts: the 
renal corpuscle (the mouth and the jawbreaker) and the renal tubule (the long and winding 
neck). The "mouth" of the renal corpuscle is actually called Bowman's capsule, which is a 
double-walled, cup-shaped structure around the glomerulus of each nephron of the vertebrate 
kidney. It serves as a filter to remove organic wastes, excess inorganic salts, and water and the 
"jawbreaker" is actually called the glomerulus.  The glomerulus consists of a tuft of capillaries 
situated within a Bowman's capsule at the end of a renal tubule in the vertebrate kidney that 
filters waste products from the blood and thus initiates urine formation.  The renal tubule 
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consists of the proximal tubule called the loop of Henle.  The loop of Henle is a long U-




Figure 1.2 Schematic diagram of cross section of kidney linking structure to function. Direction of 




The glomerulus is capillary blood vessels actively involved in the filtration of the blood to form 
urine. The glomerulus is one of the key structures that make up the nephron, the functional unit 
of the kidney. 
 
 
Figure 1.3 Schematic Cross section of glomerulus, showing the flow of blood and filtrate. 






The kidney contains approximately one million individual filtering units called glomeruli 
composed of specialized capillaries. The ultrafiltration of plasma in the kidney occurs through 
the capillary wall of the glomerulus (Figure 1.3).  The glomerular filtration barrier (GFB) is made 
up of glomerular endothelial cells (GEC’s), glomerular basement membrane (GBM) and the 
podocyte cell layer with their ‘slit diaphragms’ (Patrakka and Tryggvason 2010).  Present data 
suggest that all three layers of the glomerular capillary wall need to be intact to maintain normal 
filtration function. However, the studies performed during the last decade have underlined the 
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role of the podocyte in the filtering process (Patrakka and Tryggvason 2009).  Injury to the 
filtration barrier in renal disorders leads to protein leakage to urine (proteinuria) and progressive 
renal disease.  
 
1.2.3 Glomerular endothelial cells (GECs)  
The endothelial cells of the glomerulus are highly fenestrated.  The fenestrae are 70–100 nm in 
diameter and constitute 20–50% of the glomerular capillary surface area. As the fenestrations 
are huge compared to the size of albumin, the glomerular epithelial cells (GECs) have not been 
believed to play an important role in the barrier function for protein filtration. The GECs are, 
however, covered by an endothelial cell surface layer (mainly glycocalyx) that may hinder the 
passage of albumin and other plasma proteins into the GBM (Figure 1.4).  GECs are likely to be 
critically involved in the formation and maintenance of the filtration barrier, and probably also act 







Figure 1.4.  Glomerular filtration occurs through the capillary wall into the urinary space. The 
capillary wall contains an innermost fenestrated endothelium with glycocalyx, the glomerular 
basement membrane (GBM), and a layer of podocytes with interdigitating foot processes 
connected by slit diaphragms  (Adapted from (Patrakka and Tryggvason 2010)).
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1.2.4 Glomerular basement membrane (GBM)  
The GBM forms a structural foundation of the glomerular capillary to which endothelial and 
podocyte cells are anchored on both sides (Figure. 1.5). The main components of the GBM 
include type IV collagen, laminin, proteoglycans and nidogen. The triple-helical type IV collagen 
molecules of mature GBM are composed of a3, a4, and a5 chains.  The podocyte is a highly 
specialised epithelial cell covering the outside of the glomerular capillary (Faul, Asanuma et al. 
2007).  It has large cytoplasmic projections (major process) that divide into long thin processes 
termed foot process, close to the glomerular capillary (Figure 1.5).  The slit diaphragm divides 
the plasma membrane of the foot processes into basal, apical and lateral surfaces (Patrakka 
and Tryggvason 2010).  Defects of either the GBM or in the slit diaphragm can cause leakage of 





Figure. 1.5. Schematic picture of podocyte foot processes. Foot processes are basally anchored 
to the components of the GBM via a3b1 integrin, tetraspanin CD151 and ab dystroglycan. These 
transmembrane proteins are linked to the actin cytoskeleton via several adaptor proteins. uPAR 
receptor is also found at the basal surface of foot processes in where it probably mediates its 
actions through avb3-integrin.  Vitronectin, the extracellular ligand of avb3-integrin, is induced 
during proteinuria and activate uPAR signaling in podocytes. The slit diphragm protein complex is 
linked to actin cytoskeleton. Apical surface of podocytes contain podocalyxin and Glepp1. 
Podocalyxin is connected to actin via adapter proteins. The actin cytoskeleton of foot processes 
contains actin-associated proteins a-actinin-4 and synaptopodin, and interconnects three plasma 
membrane domains of foot processes together (Adapted from (Patrakka and Tryggvason 2010)). 
 
1.2.5 Podocyte 
The podocyte is a highly specialized epithelial cell covering the outside of the glomerular 
capillary (Faul, Asanuma et al. 2007). The podocyte has a prominent cell body and large 
cytoplasmic projections (major processes) that divide into long thin processes, termed foot 
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processes, close to the glomerular capillary (Figure. 1.5). The foot processes are attached firmly 
to the underlying GBM and arranged in a highly organized way so that they envelope the 
capillary wall in an interdigitating ‘‘comb-like” fashion. Foot processes from adjacent podocytes 
are interconnected by a specialized cell–cell junction of the podocyte, termed the slit diaphragm. 
The slit diaphragm divides the plasma membrane of foot processes to the basal, the apical, and 
the lateral surfaces. In the cytoplasm, these three surfaces are interconnected via the actin-
based cytoskeleton. Podocyte foot processes with different plasma membrane domains have 
essential roles in the maintenance of the glomerular filtration barrier.   
 
1.2.6 The slit diaphragm 
The slit diaphragm is a highly specialized cell–cell junction of podocytes that interconnects 
adjacent foot processes. Rodewald and Karnovsky in 1974 proposed that the slit diaphragm has 
a structured, zipper-like architecture with pores that are smaller than albumin, and therefore 
could serve as a barrier for protein filtration (Rodewald and Karnovsky 1974). Although this 
classic model was proposed over 35 years ago, it was only during the last decade that the 
molecular architecture of the slit diaphragm started to unravel.  The slit diaphragm protein 
complex is composed of proteins common for most cell–cell junctions, including cadherins and 
catenins, but importantly, also of proteins that are not generally found elsewhere in the body 









Figure 1.6: Schematic picture of the slit diaphragm components. The slit diaphragm complex is 
extracellularly formed of at least nephrin, Neph1–3, P-cadherin, VEcadherin, Fat1, and Jam4. 
Nephrin and cadherin proteins probably interact in a homophilic fashion in the center of the slit 
diaphragm. Intracellularly, a number of adapter proteins are involved in linking the slit diaphragm 
to actin (Adapted from (Patrakka and Tryggvason 2010)). 
 
The filtration barrier has a net negative electrical charge therefore the movement of large 
negatively charged molecules is restricted more than molecules with a positive or neutral 
charge. Proteins are negatively charged and are not freely filtered by the glomerulus. 
 
Podocin is a hairpin-shaped integral membrane protein with both ends directed into the 
intracellular space.  Podocin interacts directly with nephrin, Neph1 and Cd2ad (Sellin, Huber et 
al. 2003); (Schwarz, Simons et al. 2001), and seems to be essential for the recruitment of 
nephrin to the slit diaphragm (Schwarz, Simons et al. 2001).  The essential role of podocin in 
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the glomerular barrier has been shown in podocin deficient mice which lack slit diaphragms and 
die perinatally due to massive proteinuria (Roselli, Heidet et al. 2004).  Trpc6 is found in the slit 
diaphragm and some Trpc6 mutations found in patients result in increased amplitude and 
duration of calcium influx after stimulation.  Together, these results suggest that impaired slit 
diaphragm signalling is involved in the development of ‘‘Trpc6 nephropathy”.  Three cadherin 
proteins, a large protocadherin Fat1, P-cadherin, and vascular endothelial cadherin (VE-
cadherin) have been localized to the slit diaphragm (Patrakka and Tryggvason 2009). Fat1 is a 
huge protein with 34 tandem cadherin-like repeats, and it is essential for normal filtration barrier 
as Fat1 knockout mice lack slit diaphragms and exhibit proteinuria (Ciani, Patel et al. 2003).  P-
cadherin, on the other hand, does not seem to be essential for the functional renal filtration 
barrier, whereas the role of VE-cadherin in the podocyte is so far unknown (Patrakka and 
Tryggvason 2009). 
 
Podocytes contribute to the specific size and charge characteristics of the glomerular filtration 
barrier, and their damage leads to a retractions of their foot processes and proteinuria (Laurens, 
Battaglia et al. 1995); (Pavenstadt 1998).  Podocyte injury leads to many glomerular diseases, 
including minimal-change nephropathy, focal segmental glomerulersclerosis (FSGS), 
membranous glomerulopathy, diabetes mellitus and lupus nephritis (Somlo and Mundel 2000); 
(Kerjaschki 2001).  Currently the pathogenic role of foot process effacement in proteinuria is not 
well understood.   
 
In human genetics much progress has been made toward a molecular understanding of the slit 
diaphragm and the modulators of foot process architecture. In the past 15 years, human genetic 
studies revealed that mutations in the genes encoding nephrin (Kestila, Lenkkeri et al. 1998) 
podocin (Boute, Gribouval et al. 2000), phospholipase C ε  (Hinkes, Wiggins et al. 2006), and 
coenzyme Q10 biosynthesis mono-oxygenase 6 (Heeringa, Chernin et al. 2011) give rise to 
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early-onset proteinuria.  Additionally, adult onset proteinuria such as FSGS is associated with 
mutations in the genes encoding α-actinin 4 (Kaplan, Kim et al. 2000), CD2AP (Kim, Wu et al. 
2003), INF2 (Brown, Schlondorff et al. 2010), TRPC6 (Reiser, Polu et al. 2005); (Winn, Conlon 
et al. 2005); (Heeringa, Moller et al. 2009) and synaptopodin (Dai, Wang et al. 2010).  Mutations 
in LMX1B, which encodes a transcription factor for collagen, result in podocyte abnormalities 
due to impaired cell adhesion to the abnormal GBM (Morello, Zhou et al. 2001). Similarly, 
mutations in the gene encoding laminin β2, another component of the GBM, lead to podocyte 
injury and proteinuria (Zenker, Aigner et al. 2004). Finally, recent exome sequencing as well as 
a whole-genome linkage analysis revealed MYO1E mutations in childhood proteinuric disease 
and FSGS; MYO1E encodes a mutant form of nonmuscle class I myosin (Mele, Iatropoulos et 
al. 2011); (Sanna-Cherchi, Burgess et al. 2011). 
 
These gene polymorphisms are not directly linked to podocyte-specific defects, but this is an 
area of active research at this time.  A large locus containing numerous genes was recently 
identified in African-American populations (Kao, Klag et al. 2008); (Kopp, Smith et al. 2008).  
Initial studies revealed MYH9 as a likely gene candidate in this locus.  This was an attractive 
hypothesis, given previous work showing that MYH9 is responsible for two genetic causes of 
proteinuria: Epstein and Fechtner syndromes Table 1.1 (Arrondel, Vodovar et al. 2002).  
Interestingly, further work revealed that the likely candidate gene conferring risk for kidney 
disease is apolipoprotein L1 (APOL1), a molecule that is known for its trypanolytic properties 
and that confers an evolutionary advantage in African-Americans (Genovese, Friedman et al. 
2010).  Furthermore, common variations in GPC5 (which encodes glypican 5) are also 




Table 1.1: Candidate genes implicated in various forms of Nephrotic Syndrome 
Gene Location Protein Inheritance Gene Usual onset 
NPHS1 19q13.1 Nephrin Slit 
diaphragm 
AR Congenital nephrotic 
syndrome, characteristic 
changes 
NPHS2 1q25-31 Podocin Slit 
diaphragm 
AR Congenital nephrotic 
syndrome,or early onsets 
SRNS 
PLCE1 10q23-24  Phospholipase C 
epsilon 1  
Intracellular AR Early onset SRNS:Diffuse 
mesangial sclerosis (DMS); 
FSGS 
WT1 11p13 Wilm’s tumor 1 Intracellular AD Early onset SRNS, Denys-
Drash or Frasier syndrome; 
DMS      (Deny’s Drash 
Syndrome); FSGS (Frasier 
syndrome) 
LAMB2 3p21 Laminin-β2 Glomerular 
basement 
membrane 
AR Pierson syndrome, early 
onset SRNS: DMS 
(Syndromic): FSGS 
(Isolated) 




SD Adult onset SRNS 
(heterozygous), early onset 
FSGS (homozygous), 
FSGS 
ACTN1 19q13 Alpha-Actinin 4  Intracellular AD Adult onset SRNS 
(incomplete penetrance, 
slow progression); FSGS 
TRPC6 11q21-22 Transient receptor 
potential cation 
channel, homolog of 6  
Cell surface AD Adult onset SRNS;FSGS 
INF2 14q32 Inverted formin 2 Intracellular AD Adult onset SRNS;FSGS 
LMX1B 9q34.1 LIM-homeodomain 
transcription factor1β 
Intracellular AD Nail-patella 
syndrome;SRNS 





1.3 History of Nephrotic Syndrome 
The term nephrotic syndrome (NS) was first described by Leiter in 1931 “to differentiate the 
association of massive proteinuria, oedema and hypercholesterolemia “due to what maybe 
glomerulonephritis” (Leiter 1931).  NS is a clinical syndrome characterised by heavy proteinuria 
(>40mg/m2 per hour or 50mg/kg per day), hypoalbuminemia (albumin ≤2.5mg/dL) and 
hyperlipidemia (serum cholesterol >200mg/dL or 6.5mmol/L) with or without oedema (Gipson, 
Massengill et al. 2009).  It is also recommended that in children where a 24 hour urine collection 
is difficult, then the use of the protein: creatinine ratio on a spot early morning sample of urine 
with a urine protein: creatinine (Up/Ucr) ratio ≥2.0, be used to quantify massive proteinuria 
(Hogg, Furth et al. 2003).  Proteinuria results when there is a weakness in the filter vessel wall 
that allows protein to leak into the urine.  An early event is the loss of integrity of foot processes 
and the slit diaphragm, leading to foot-process fusion, altering the filtration barrier with resultant 
protein in the urine (proteinuria) and blood in the urine (haematuria) (Figure 1.7)  (Workshop by 
the British Association for Paediatric Nephrology and Research Unit, Royal College of 










Figure 1.7.  A schematic representation of a typical functioning glomeruli versus a diseased 
glomerulus presenting with proteinuria and hematuria (Adapted from (Falk 2008)). 
 
NS can be classified according to age of onset, as congenital nephrotic syndrome (CNS) that 
presents from birth to three months, infantile NS presenting after three months to one year of 
age, and childhood onset NS presenting after one year of age, with those children presenting 
after eight years of age being classified as having late onset NS (Bhimma 2006).  
NS has been separated into 2 broad categories on the basis of patients response to standard 
steroid therapy, i.e., steroid sensitive nephrotic syndrome (SSNS) and steroid resistant NS 
(SRNS) (Ruf, Lichtenberger et al. 2004).  Most children respond to steroid therapy and show a 
favourable long-term outcome. However, 10–20% of the patients show resistance to steroid 
therapy and are classified as SRNS.  These patients tend to progress to end stage kidney 
disease (ESKD) due to progressive damage of the glomerular filtration barrier  and will 
eventually need renal replacement therapy (Yu, Ding et al. 2005).   
NS is further categorised into secondary, primary, idiopathic, or familial NS.  There are different 




Focal segmental glomerulosclerosis (FSGS) and membranous nephropathy (MN).  The latter is 
rare in children (Bhimma, Naicker et al. 2013) 
Minimal change disease and FSGS may represent opposite ends of one pathophysiological 
process or distinct disease entities.  By contrast, membranous nephropathy is a distinct disease 
associated with prominent immune complex diseases located between glomerular podocytes 
and the GBM (Eddy and Symons 2003).  MCD is characterised by foot process effacement 
(Figure 1.8) and loss of the normal charge barrier such that albumin leaks out and proteinuria 




Figure 1.8.  A schematic representation of a proteinuria leakage demonstrating Minimal Change 
disease (Adapted from (Falk 2008)). 
 
Each kidney is made up of approximately one million tiny filters called “glomeruli”. FSGS 
indicates that some segments of the kidney filters are scarred thus leading to the release of 
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Figure 1.9.  Schematic and light micrograph of cross-section of A & B: normal glomeruli; C & D 
glomeruli with focal segmental glomerulosclerosis (Adapted from (Falk 2008)). 
 
In SRNS, approximately 75% of patients exhibit renal histologic features of FSGS and 20% 
demonstrate minimal-change disease.  Conversely, in SSNS, renal histologic features indicate 
minimal change disease in 80% of cases and FSGS in 20% (Fuchshuber, Jean et al. 1995).  
Approximately 10% of children and 50% of adults with idiopathic NS have SRNS, fail to respond 
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to immunosuppressive treatment and progress to ESKD) within seven years of diagnosis 
(Korbet 2002).   
The worldwide incidence of NS in children in developed countries ranges from 2 to 7 per 
100 000 and the prevalence from 12 to 16 per 100 000 children, with approximately a six fold 
higher rate reported among those with African and South Asian ancestry  (Eddy and Symons 
2003); (Bhimma, Adhikari et al. 2006); (Copelovitch, Sam Ol et al. 2010); (Ingulli and Tejani 
1991); (Mubarak, Lanewala et al. 2009). 
There have been a few longitudinal studies of children with NS (Table 1.2).  Most cohort studies 
have been retrospective chart reviews with limited access to clinical data.  The few prospective 
studies on childhood NS are registries of short follow-up time, limited clinical data, in ethnically 
homogenous populations (Hussain, Zello et al. 2013). 
Previously it has been reported by Srivastava (Srivastava 1987) that the overall incidence of 
childhood idiopathic NS has been generally stable, however there has been several reports over 
the years that the histological pattern is changing.  There incidence of FSGS seems to be 
increasing and this may be due to ethnic origins that may affect histological variants and the 
response to immunosuppressive treatment (Bhimma, Adhikari et al. 2006); (Bhimma, Adhikari et 
al. 2008); (Ingulli and Tejani 1991).   
Several reasons have been suggested to explain ethnic differences in the incidence of the 
disease.  These include high prevalence of infections, lower socio-economic status with 
inequalities in access to health care resources, genetics, and environmental factors.  The onset 
of NS has been linked to environmental exposures such as mercury exposure (in adults), history 
of atopy, and immune response (George 2011); (Meadow and Sarsfield 1981); (Jahan, Hanif et 
al. 2011); (Cheung, Wei et al. 2004). There have been renal effects found in children as a result 
of low-level of exposure to cadmium, lead, mercury, and arsenic, however, the role of these 
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exposures in NS has not been explicitly identified (de Burbure, Buchet et al. 2006).  There is 
some literature describing the associations between childhood NS and socio-demographic 
factors, but they are mostly cross-sectional studies or prospective studies with limited follow-up, 
thus restricting our understanding of the determinants of health for children with NS (Vance, 
Fazan et al. 1980, Vance and Pless 1983); (Naidoo, Moodley et al. 1987); (Soliday and Lande 
2002, Soliday, Moore et al. 2002); (Hall, Thorley et al. 2003); (Ruth, Landolt et al. 2004); (Guha, 
De et al. 2009); (Mitra and Banerjee 2011).  As a result, there is a significant gap in the literature 
on the role of environmental and socio-demographic modifiers of NS in children in the long-term.  
Socio-demographic factors such as economic status, child quality of life and parental well-being, 
environmental factors such as exposures to lead or heavy metals, and serological modifiers, 
clinical factors such as hypertension or body mass index, or genetic factors may account for the 
variability in incidence and progression rates of the disease among various ethnic groups. 
Ethnic origin may affect the histological expression of the diseases in children with NS (Eddy 
and Symons 2003). Chanchlani et al recently reported that incidence and response to treatment 
of NS varies by ethnicity (Chanchlani R 2016). Bhimma et al reported that there are distinct 
differences in the distribution of the various forms of NS within the various population groups in 
Durban, KwaZulu-Natal (Bhimma, Coovadia et al. 1997). Whilst the disease in the Indian 
children was shown to parallel that seen in developed countries, with minimal-change disease 
predominating, the pattern of disease was very different in the black children. Black children had 
a paucity of minimal-change NS with only 6.8% being considered to have typical steroid-
sensitive minimal-change disease. The commonest form of NS seen in black children until a few 
years after the introduction of the hepatitis B virus vaccine into the Expanded Programme for 
Immunization in Childhood was Hepatitis B virus-associated membranous nephropathy, which 
accounted for 86% of cases of NS in black children in Durban, South Africa (Bhimma, Coovadia 
et al. 1997).   
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Table 1.2 Observational studies in Children with Nephrotic Syndrome 
Author  Year N Ethnicity   Mean age at Onset± Male (%)  Mean follow-up time± Steroid  
       SD, yrs (Range)    SD, yrs (Range)  Resistant (%) 
Inguli  1991 177 Black and Hispanic  7.3 ± 4.6   No data  8.25 ± 4.3  15.3% 
       (1.0-16.75)    (1-15) 
   65 Caucasian  7.8 ± 4.8     8.8 ± 4.1   6.2% 
       (2-14.8)     (2-14.8) 
Bircan  2002 132 Turkish   4.9 ± 3.56  61.2%  3.4 ± 2.31  13.2% 
       (1-15)     (1-6) 
Ozkaya  2002 392 Turkish   4.6 ± 3.4   59.2%  2   23%b 
            (0.9-16)a 
Kim  2005 103 Caucasian  4.3 ± 3.5   51%  No data   3.6% 
   96 African American  8.2 ± 5.2     No data   11% 
Bhimma  2008 816 Black and Indian  4.8   60.4%  2.5   27.3% 
       (1.2-16)     (0.1-16.5) 
Chang  2009 99 Chinese   8.35 ± 4.61  73.7%  5.06 ± 4.35  N/Ae 
       (2-18) 
Mubarak  2009 538 Pakistani   9.79 ± 4.59  64.4%  No data   31.1% 
       (0.8-18) a 
Otukesh  2009 73 Iranian   5.9   52.0%  6.0 ± 4.2   100% 
            (0.5-16) 
Copelovitch 2010 112 Cambodian  8.95   63.4%  15.1   16.25% 




Banaszak  2012 76 Caucasian (Poland) c 2.7 (median)  54.5%  No data   15.8% 
   102 Caucasian (Poland) d 3.3 (median)  68%  No data   31.3% 
Prospective studies 
Kumar  2003 290 Northern and Eastern Indian 7.9 ± 5.1   73.4%  No data   38%b 
Wong (Registry)  2007 49 New Zealand European 6.1 ± 3.8   71.4%  1   19.6% 
    Maori, Pacific Islander, Asian 
Other 
Bakkali (Registry) 2011 231 No data (Netherlands) 5.08   67.1%  4   N/A e 
a indicates age of study group, where age at onset not specified 
b estimated based on participants diagnosed with FSGS 
c indicated patients treated with NS between 1986-1995 
d indicated patients treated with NS between 1996-2005 




The pathogenesis of NS, in the context of observed immunological dysfunction, and its 
relationship with proteins of the slit diaphragm and the podocyte cytoskeleton, is unclear. A 
unifying hypothesis that combines the immunological perturbations with abnormal function at the 
level of the slit diaphragm is lacking. Figure. 1.10 summarizes the current view on pathogenesis 
(Sinha and Bagga 2012). 
 
Figure. 1.10 Pathogenesis of idiopathic nephrotic syndrome. Schematic view of podocyte foot 
process demonstrates its components of the slit diaphragm complex, formed by nephrin, Neph1 
and podocin (Po), and the actin cytoskeleton, which also receives inputs from the basolateral 
domain of the foot process, containing the α3β1 integrins and α and β dystroglycans (Adapted 




The dominant paradigm in NS is an imbalance between T helper 1 (Th1) and T helper 2 (Th2) 
cytokines, and that a soluble mediator, presumably IL-13, increases glomerular permeability. 
Other molecules suggested as mediators include soluble urokinase plasminogen activator 
receptor (suPAR), vascular endothelial growth factor (VEGF), and angiopoietin-like-4 
(ANGPTL4). Signaling through nuclear factor kappa B (NF-κB) and toll like receptors (TLRs) 
mediated pathways may polarize adaptive immune responses towards Th2 cells, or directly 
increase CD80 expression in podocytes.  
 
An imbalance of Th17 and T regulatory responses allows persistent CD80 activation on 
podocytes, and/or helper responses. Finally, therapeutic agents have direct effects on 
podocytes; glucocorticoids (G) on gene expression, calcineurin inhibitors (C) on stabilization of 
synaptopodin (S) or inhibition of TRPC6 channel, and binding of rituximab (R) to the SMPDL-3b 
protein. These findings demonstrated the importance of the podocyte in the pathogenesis of NS, 
which led to the proposal that most cases of NS are caused by podocyte defects.  Therefore this 
defect was termed ‘podocytopathies’ (Wiggins 2007).   
 
More recently single gene mutations affecting podocyte differentiation and function have been 
described, particularly in steroid resistant disease, predicting unresponsiveness to 
immunosuppressive therapy. SRNS may be caused by mutations in genes that encode proteins 
that play key roles in maintaining podocyte ultrastructure (Niaudet 2013). 
 
1.5 Genetics of Nephrotic Syndrome 
Genetic mutations are present in 10-20% of patients with SRNS, and in a higher proportion of 
patients with familial NS (13%) for autosomal recessive and 30% in autosomal dominant NS 
(Gigante, Piemontese et al. 2011); (Lipska, Balasz-Chmielewska et al. 2013).  The age of 
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disease onset is an important predictor of the odds of findings an abnormality in a particular 
gene linked to SRNS. To date there are more than 30 genes that have been associated with 
hereditary SRNS (McCarthy, Bierzynska et al. 2013). In 1998, Kestila et al. (Kestila, Lenkkeri et 
al. 1998) discovered that the NPHS1 gene, encoding the podocytic protein nephrin, is mutated 
in the Finnish type of congenital NS (CNS). This finding was the first proof of concept for the 
heredity of childhood NS. In 2007, Hinkes et al. (Hinkes, Mucha et al. 2007) found that 
mutations in NPHS1, NPHS2 (encoding podocin), WT1 (exons 8 and 9) and LAMB1 (encoding 
laminin-β2) are causes of two thirds of cases of NS with onset in the first year of life.  Mutational 
analysis of seven podocyte genes (NPHS1, NPHS2, WT1, CD2AP, ACTN4, TRPC6  and 
PLCE1) in 19 non-familial childhood-onset, steroid resistant, biopsy-proven FSGS patients 
revealed variants of NPHS1, NPHS2, WT1 and CD2AP  that could be the cause of the disease 
in four subjects (21%).  In addition, these results have suggested the role of combinations of 
genetic variants (biogenic heterozygosity) in the  pathogenesis of steroid-resistant FSGS  
(Lowik, Levtchenko et al. 2008);(Santin, Bullich et al. 2011) proved the clinical utility of a genetic 
testing algorithm, for SRNS occurring before adolescence, based on an analysis of NPHS1, 
NPHS2, WT1 and PLCE1 genes. On the other hand, Hasselbacher et al. (Hasselbacher, 
Wiggins et al. 2006) and Matejas et al. (Matejas, Hinkes et al. 2010) indicated that analysis of 
the LAMB1  gene, which is mutated in Pierson syndrome (OMIM #609049), could be included in 




 The NPHS1 gene that encodes for nephrin was identified as the causative gene in the most 
common type of CNS viz. CNS of the Finnish-type (CNF) (Kestila, Lenkkeri et al. 1998).  CNS of 
the Finnish type is an autosomal recessive disorder and is the most common type of CNS found 
in Finland and other parts of the world (Bolk, Puffenberger et al. 1999).  The renal histology of 
CNS ranges from microcystic dilatation of tubules to minimal change disease, FSGS and diffuse 
mesangial sclerosis (Hinkes, Mucha et al. 2007); (Santin, Garcia-Maset et al. 2009). NPHS1 
mutations has also been reported in childhood (Philippe, Nevo et al. 2008) and adult-onset 
SRNS (Santin, Garcia-Maset et al. 2009).  
The NPHS2 gene encodes for podocin, an integral membrane protein found exclusively in 
glomerular podocytes. Podocin is a 383-amino acid protein of approximately 42kD a lipid-raft-
associated protein localized at the slit diaphragm, where it is required for the structural 
organization and regulation of the glomerular filtration barrier.  NPHS2 encodes an integral 
membrane protein with one transmembrane domain (105–121 aa) and a 262-amino-acid 
carboxy-terminal cytoplasmic tail. The transmembrane domain and most of the cytoplasmic tail 
are homologous to the corresponding regions of the stomatin family proteins. Podocin, however, 
extends beyond the stomatin-like sequences at both the N and C termini (97 aa and 36 aa, 
respectively), which show no homology with any known protein sequence (Boute, Gribouval et 
al. 2000). It is a membrane-anchored protein of the stomatin family with a predicted hairpin-like 
structure, such that both ends of the protein are located in the cytoplasm (Roselli, Gribouval et 
al. 2002). Podocin was shown to accumulate in an oligomeric form in lipid raft microdomains 
and to localize to the slit diaphragm area (Roselli, Gribouval et al. 2002), where it interacts with 
other slit diaphragm components, such as nephrin and CD2AP (Schwarz, Simons et al. 2001); 
(Huber, Kottgen et al. 2001).  Homozygous and compound heterozygous mutations of this gene 
are most frequently found in children with familial SRNS and less commonly with sporadic 
SRNS. To date, more than 50 NPHS2 mutations have been reported in both familial and 
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sporadic cases of SRNS (Roselli, Moutkine et al. 2004); (Caridi, Bertelli et al. 2003); (Cybulsky, 
Takano et al. 2009); (Ohashi, Uchida et al. 2003); (Ye, Dhillon et al. 2001); (You, Huo et al. 
2008). Half are missense mutations spread over the entire length of the coding sequence of the 
gene, and the rest are nonsense, protein truncating mutations, insertions, and deletions. 
Mutations in genes that encode key podocyte and slit diaphragm proteins are implicated in the 
pathogenesis of SRNS (Hinkes, Mucha et al. 2007). NPHS2 mutations are present in 10–55% 
of patients with sporadic and familial SRNS of European ancestry (Hinkes, Mucha et al. 2007); 
(Karle, Uetz et al. 2002); (Weber, Gribouval et al. 2004); (Ruf, Lichtenberger et al. 2004); 
(Caridi, Bertelli et al. 2001); (Berdeli, Mir et al. 2007); (Frishberg, Rinat et al. 2002); (Yu, Ding et 
al. 2005).  There is a strong regional bias with 10 to 30 percent of cases of sporadic SRNS in 
children in the middle east and Europe having this mutation (Weber, Gribouval et al. 2004); 
(Caridi, Bertelli et al. 2001); (Karle, Uetz et al. 2002); (Frishberg, Rinat et al. 2002); (Caridi, 
Bertelli et al. 2003); (Berdeli, Mir et al. 2007), whereas the frequency of mutations is low in 
African-Americans (Chernin, Heeringa et al. 2008). On the other hand, inter-ethnic variations 
are striking and only a small proportion of Israeli Jewish and Asians show similar mutations (Yu, 
Ding et al. 2005); (Maruyama, Iijima et al. 2003); (Cho, Lee et al. 2008). Children with NPHS2 
mutations have early onset of disease, rapid progression to ESKD and associated cardiac 
defects in some cases (Frishberg, Feinstein et al. 2006).  
Most patients with two NPHS2 pathogenic mutations develop NS before the age of six years, 
present mostly with FSGS, do not respond to immunosuppressive therapy, reach ESKD before 
the first decade of life, and have a minimal risk for recurrence of FSGS after kidney 





The NPHS2 gene mutations have also been identified in 51% of CNS cases of European origin 
and also in adult onset forms of FSGS (Hinkes, Mucha et al. 2007); (Tsukaguchi, Sudhakar et 
al. 2002) The incidence of NPHS2 gene mutations in familial SRNS was found to be 40% in 
European and American children, 29% in Turkish and 0% in Japanese and Korean children 
(Lowik, Groenen et al. 2009). 
Mutations in the NPHS2 gene cause an autosomal recessive form of SRNS with an early onset 
of the disease and renal histology of FSGS (Boute, Gribouval et al. 2000). The NPHS2 gene 
mutations have also been identified in 51% of CNS cases of European origin and in adult onset 
forms of FSGS (Hinkes, Mucha et al. 2007); (Tsukaguchi, Sudhakar et al. 2002).  
Hinkes et al (Hinkes, Mucha et al. 2007) conducted an impressive multinational collaboration, 
on 430 patients with SRNS, the vast majority of whom were the only affected family member, 
although the series did include 23 families with more than one affected member. The patients 
were screened for mutations in NPHS2 by direct sequencing of all eight exons of the gene. 
Eighty-two patients (19% of the total) had mutations in NPHS2. In the families with more than 
one affected member, the proportion with NPHS2 mutations rose to 39%. In patients with two 
NPHS2 mutations, the authors report that approximately 40% had one truncating (frameshift or 
nonsense) mutation and an additional 30% had homozygous R1308Q mutations (the 
“founder”NPHS2 mutation identified by Boute et al) (Boute, Gribouval et al. 2000).  These two 
groups of individuals nearly all developed NS at an early age (6 yr, with a mean age of onset 2 
yr). The remaining 30% of patients with other mutations or variants in NPHS2 had later onset 
disease without any further specific link between any given genotype and age of onset (although 
the numbers of patients with each genotype were small). Mutation type did not affect rate of 
deterioration, time from onset to ESKD being the same in all groups.  Although this represents 
real progress, even within the groups with early presentation there was still a wide range of age 
of onset. Also, 80% of the collection with steroid-responsive NS did not have any abnormality of 
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NPHS2, so their proteinuria remains unexplained; clearly, there is more work to be done.  The 
power of large multinational studies such as this one will be essential if analyses of genotype–
phenotype relationships in NS are to yield informative conclusions.  Ideally, genetic analysis 
should be more widely available as a diagnostic and prognostic aid in patients presenting with 
NS; however, at present, clinicians will need further guidance from geneticists about the 
interpretation of genotype–phenotype relationships.  
The polymorphism R229Q is one of the most commonly reported podocin sequence variations. 
The arginine residue at protein position 229 is highly conserved across species, and arginine-to-
glutamine substitution R229Q has been reported to alter functional properties of podocin in vitro 
and possibly in vivo (Zhang, Marlier et al. 2004). It has been found repeatedly with slightly 
increased frequency in SRNS compared to healthy controls (Weber, Gribouval et al. 2004); 
(Franceschini, North et al. 2006). On the other hand, subsequent studies reported similar 
frequencies of this polymorphism in SRNS and in normal subjects (5.13 and 3.75 %, 
respectively) (Ruf, Lichtenberger et al. 2004). Further, the influence of the R229Q functional 
variant on microalbuminuria was investigated. First, the R229Q functional variant was 
associated with microalbuminuria in the general population (Pereira, Pereira et al. 2004). In the 
second study, the R229Q variant did not appear to alter the risk of proteinuria in general 
population and in a diabetic population (Tonna, Needham et al. 2008).  It is important to 
understand the role of the R229Q function in ESRD that will help us understand aspects of the 
podocyte and glomerular physiology and also the role in disease prediction and prevention. 
 
APOL1 and MYH9 genes are located on chromosome 22.  APOL1 gene encodes a secreted 
high-density lipoprotein that binds to apolipoprotein A-I. Apolipoprotein A-I is a relatively 
abundant plasma protein and is the major apoprotein of HDL (High Density Lipoprotein).  The 
1000 Genomes Project database led to two distinct sets of variants in the APOL1 gene, termed 
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alleles ‘G1’ and ‘G2’, being discovered as the main cause of the association of the 22q12.3 
region with end-stage renal disease in African Americans, as well as the underlying cause of all 
the associations originally reported in 2008  (Genovese, Friedman et al. 2010); (Tzur, Rosset et 
al. 2010).  Both the G1 and G2 alleles alter the amino acid sequence of the APOL1 protein. 
Notably, the altered protein product confers innate resistance against Trypanosoma brucei 
rhodesiense, a sub-Saharan parasite that causes African trypanosomiasis (or ‘sleeping 
sickness’), thus providing a plausible biologic explanation for the high frequency of these alleles 
in individuals of African descent. 
 
Mapping by admixture linkage disequilibrium (MALD) localized an interval on chromosome 22, 
in a region that includes the MYH9 gene, which was shown to contain African ancestry risk 
variants associated with certain forms of ESKD (Kao, Klag et al. 2008); (Kopp, Smith et al. 
2008).  MYH9 encodes nonmuscle myosin heavy chain IIa, a major cytoskeletal nanomotor 
protein expressed in many cell types, including podocyte cells of the renal glomeruli.  Dense 
mapping of MYH9 identified individual single nucleotide polymorphisms (SNPs) and sets of such 
SNPs grouped as haplotypes that were found to be highly associated with a large and important 
group of ESKD risk phenotypes, which as a consequence were designated as MYH9-
associated nephropathies (Bostrom and Freedman 2010). These included HIV-associated 
nephropathy (HIVAN), primary nonmonogenic forms of FSGS and hypertension affiliated 
chronic kidney disease not attributed to other etiologies (Bostrom and Freedman 2010). The 
MYH9 SNP and haplotype associations observed with these forms of ESKD yielded the largest 
odds ratios (OR) reported to date for the association of common variants with common disease 
risk (Winkler, Nelson et al. 2010). Two specific MYH9 variants (rs5750250 of S-haplotype and 
rs11912763 of F-haplotype) were designated as most strongly predictive on the basis of 
Receiver Operating Characteristic analysis (Nelson, Freedman et al. 2010). However, despite 
intensive efforts including re-sequencing of the MYH9 gene no suggested functional mutation 
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has been identified (Nelson, Freedman et al. 2010); (Winkler, Nelson et al. 2010). This led to 
Winkler et al re-examining the interval surrounding MYH9 and to the detection of novel 
missense mutations with predicted functional effects in the neighbouring APOL1 gene, which 
are significantly more associated with ESKD than all previously reported SNPs in MYH9. 
  
To date there has been one published report by Kasembali et al (Kasembeli, Duarte et al. 2015) 
in HIV associated nephropathy in Black South Africans in adult patients.  This study showed a 
strong association of APOL1 variants and biopsy-confirmed HIVAN driven by interaction 
between APOL1 and untreated HIV infection.   Qulu et al (Qulu 2016) at my institution undertook 
a study to determine the role of genetic variants at the APOL1 locus in the development of 
FSGS in South African children with idiopathic and HIVAN. For idiopathic FSGS the odds of 
carrying two copies of G1 and/or G2 risk alleles were 2.4(95%CI 0.26 to 30, p=0.38) and Inf = 
0.03 (p=0.45) for the HIV-associated FSGS in a recessive model. For HIV-associated FSGS, 
the allele frequencies were 10% for the G1 risk allele and 10% for the G2 deletion and 7% of the 
HIV with FSGS population carried high-risk genotypes compared to the controls (0%). A 
majority of the HIV-associated FSGS (71.4%) showed absence of the APOL1 G1 and G2 risk 
alleles whilst forty-seven percent of patients with idiopathic FSGS (HIV-) showed absence of the 
APOL1 G1 and G2 risk alleles. This study demonstrated that APOL1 risk variants are not 
predictors of biopsy proven HIV associated FSGS and idiopathic FSGS in the paediatric Black 





The aim of our study was to determine the existence of mutations in the NPHS2 gene in Black 
and Indian children with SRNS in KwaZulu-Natal, South Africa, using DNA genotyping and to 



















Chapter two - Methods and Results
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Manuscript submitted for Publication 
Title:  A Single NPHS2 Mutation Accounts for 27% of Steroid Resistant Nephrotic 
Syndrome in Black South African Children 
2.1 Introduction 
Nephrotic syndrome (NS), an important kidney disease in children, is the consequence of 
damage to the glomerular filtration barrier leading to significant proteinuria, hypoalbuminemia, 
hyperlipidemia, and edema. NS is classified by its response to steroid therapy as steroid 
sensitive (SSNS) or steroid resistant (SRNS) nephrotic syndrome.1 Although the majority of 
children with idiopathic NS respond to glucocorticoids and have a favorable prognosis, 
approximately 20% are SR, which is associated with repeated hospital admissions, treatment 
with immunosuppressive drugs with risk for adverse events, and often progressive loss of 
kidney function.2 Among children with idiopathic NS, the most common histological diagnosis in 
Black children in South Africa (SA) is focal segmental glomerulosclerosis (FSGS) while minimal 
change disease (MCD) is more frequently diagnosed in White and Indian children.3-5 Indian 
children living in South Africa with SRNS respond better to oral cyclophosphamide treatment 
than Black children, who are less likely to achieve complete remission (69% vs. 20% in Indians 
and Blacks, respectively).6,7 The basis for these disparities has not been explained, but has 
been hypothesized to be due in part to genetic differences predisposing to SR-FSGS.8 
 
Among the many mutations in over 30 genes causing SRNS in families or associated with 
sporadic SRNS, mutations in NPHS2 represent the most frequent cause in children.9-12 In one 
worldwide study of 430 families with NS, 18% were homozygous or compound heterozygous for 
deleterous NPHS2 mutations; of these the most common mutation was the European founder 
R138Q mutations, found in 7% of the families.13 Among children  with SRNS and congenital NS 
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enrolled in the PodoNet registry cohort recessive mutations in NPHS2 were identified 138/1088 
(12·6%) of children undergoing targeted mutational analysis; however, only 3 parents reported 
African ancestry.14  There are few reports of causative mutations in NPHS2 among African 
ancestry children in the USA with FSGS, possibly reflecting fewer children enrolled in studies or 
the absence of NPHS2 founder mutations.14,15,16  
 
NPHS2 encodes podocin, a member of the stomatin protein family, which is a transmembrane 
protein that recruits nephrin to lipid rafts in the plasma membrane. Podocin is essential for the 
maintenance of the podocyte ultrastructure and the podocyte slit diaphragm.17-20   Protein 
altering mutations in NPHS2 weaken or abrogate the podocin-nephrin interaction at the plasma 
membrane leading to a failure of the kidney filtration barrier and resultant SRNS.  Truncating 
(R138X) and certain missense mutation (e.g. R138Q and V260E) are associated with SRNS 
with an earlier age of onset, generally before the age of 6 years.13,21  
 
Genetic coding variants in APOL1, encoding apolipoprotein L1, are recessively associated with 
FSGS, with a median age of onset of 35 years, and with chronic kidney disease in persons of 
sub-Saharan African ancestry.22,23 APOL1 variants are present only on African-ancestry 
haplotypes and  restore the ability of APOL1 protein to kill T.b. rhodensiense, the causative 
agent of acute African human trypanosomiasis.22 In an African American pediatric study of 
chronic kidney disease, carriage of high-risk genotypes was associated with a lower estimated 
glomerular filtration rate (eGFR) at study entry and with FSGS histology and were enriched in 
children with NS.24 The association of APOL1 with NS in children in sub-Saharan Africa has not 




The genetic basis for the racial disparity in SRNS and FSGS histology of children with NS from 
sub-Saharan Africa is unknown, and no genetic studies have been reported to date. 
Considering the increased risk of Black children for SRNS in South Africa, we hypothesized that 
APOL1 renal risk variants, which are found only on African ancestry haplotypes, or founder 
mutations in NPHS2, might be responsible for the higher rate of SR in Black children compared 
to Indian or White South African children with NS.   
 
2.2 Materials and Methods 
2.2.1 Subjects 
Unrelated Indian and Black children (n=64) with sporadic SRNS (n=49) or SSNS (n=15) treated 
between January 2005 to December 2011 at two referral hospitals in Durban, KwaZulu-Natal 
Province, South Africa, were invited to participate in the study. The majority of black Africans in 
KwaZulu-Natal Province identify as Zulu (>95%).    
2.2.1 Inclusion criteria 
All children with primary NS were given oral prednisone (2mg/kg, maximum 60 mg) for 6 weeks 
followed by the same dose on alternative days for another 6 weeks, reduced to none over 2·5 
months.  Failure to respond to oral steroids after 6 weeks was taken as SR in accordance with 
standard criteria. 2,25 Second line treatment included oral cyclophosphamide (2mg/kg with a 
maximum dose of 100 mg daily) given as a daily dose for 8-12 weeks with angiotensin-
converting enzyme inhibitor (0·5mg/kg, maximum 10mg) and oral prednisone (1mg/kg, 
maximum 60mg) given on alternative days. Children with SRNS who did not respond to oral 
cyclophosphamide plus low dose oral prednisone received intensive treatment with intravenous 
methylprednisolone (n=11) or intravenous (IV) cyclophosphamide (n=7) or both 
methylprednisolone and IV cyclophosphamide (n=2) or tacrolimus (n=14), or both IV 
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cyclophosphamide plus tacrolimus (n=2) together with low-dose prednisone on alternative days.  
Only children not responding to oral steroids underwent kidney biopsy. Kidney biopsies were 
interpreted using light microscopy, immunofluorescence and electron microscopy. Children with 
primary SSNS or SRNS and with an eGFR of >60ml/min/1·73m2 using the modified Schwartz 
formula, 26 were eligible for entry into the study.  
2.2.3 Exclusion criteria 
Children with eGFR <60 at diagnosis were excluded because they were not given 
immunosuppression therapy.  Other exclusion criteria included those for whom histology was 
indeterminate or who were lost to follow-up or refused to participate in the study. The following 
tests were performed to exclude secondary forms of NS: antistreptolysin O titer (ASOT), 
hepatitis B and C screen, blood culture, Widal tests, Wasserman reaction, antinuclear factor, 
and testing for Epstein Barr virus, HIV, parvo virus and cytomegalovirus.  
2.2.4 Control group 
Black (n=55) and Indian (n=49) healthy blood donors were enrolled as control groups.  
Proteinuric remission was defined as a protein to creatinine ratio (PCR) <0·2 mg/mg and serum 
albumin >30g/dL; partial remission was defined as a PCR<1·9 mg/mg and serum albumin 
>25g/dL, but not meeting full remission criteria. For replication of NPHS2 results, we enrolled an 
additional 20 Black sporadic SRNS cases with biopsy-proven primary FSGS, and 18 age-
matched Black controls with no serological evidence of HIV infection, with normal kidney 
function, and no proteinuria.  
2.2.5 Informed Consent 
Written informed consent was obtained from the parents of children, and children over 7 years 
assented to be in the study. The Biomedical Research Ethics Committee of the University of 
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KwaZulu-Natal, SA and the National Cancer Institute, NIH, USA approved this study. (In 
Addendum attached) 
2.2.6 Sequencing and genotyping 
APOL1 SNPs definingG1 (rs73885319 and rs60910145) and G2 (rs717185313) were 
genotyped by ABI Custom TaqMan SNP Genotyping Assays (ABI, Foster City, California). 
NPHS2 Exons 1 through 8 were Sanger sequenced using the ABI 3700 Analyzer under 
standard conditions.  Primer sequences were from Boute et al.,9 with an additional primer pair in 
genomic regions flanking NPHS2 exon 1 (primers in Supplementary Appendix). To determine 
relatedness and the age of the NPHS2 V260E mutation, DNA from 9/14 V260E homozygous 
patients (those with remaining DNA) and 71 Black cases and controls who did not carry the 
mutation were genotyped using the Human Exome Chip (HumanExome-12 v1·2, Illumina, San 
Diego, CA). 
2.3 Statistical and Bioinformatics Methods   
We used Fisher’s exact test for categorical tests for APOL1 and NPHS2 variants, including a 
burden test comparing the number of singleton NPHS2 missense variants in cases and controls. 
We compared the age distributions between Indian and Black SRNS, and between Black SRNS 
with and without V260E homozygosity, with the Mann-Whitney test. All statistical tests and 
simulations were done in R (http://www/R-project.org).  
We determined relatedness among NPHS2 V260E homozygotes by estimating the age of the 
most recent common ancestor for the V260E mutation among subjects using coalescence 
(Supplementary Methods).27  Briefly, we examined homozygosity of Chromosome 1 SNPs typed 
on the Illumina Exome chip 12 v1·2, by plotting heterozygous and homozygous SNPs for each 
subject in the region around NPHS2.  Subjects inheriting the mutation from a recent common 
ancestor will have inherited identical segments of chromosome around the mutation from their 
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two parents, creating an extended block of homozygosity, with length determined by 
recombination since the common ancestor. We compared the observed lengths of 
homozygosity with simulation results for different numbers of generations since the common 
ancestor using the Mann-Whitney test. We further tested for consanguinity among V260E 
homozygotes by the coefficient of relatedness test implemented in PLINK.28 
 
2.4 Results 
Sixty-four unrelated children with sporadic idiopathic NS were enrolled between 2005 and 2011 
(Table 2.1). Mothers of the affected children reported no affected siblings and no familial history 
of kidney disease.  SR was significantly more frequent in Black (97%) than in Indian (58%) 
children with NS (OR 21; 95% CI: 2·8, 960; p=0·0002); for children with SRNS the median age 
of presentation was similar for Indian (86 months) and Black children (83 months).  Among 49 
children with SRNS undergoing biopsy, FSGS was the most common histopathology in both 
Black (80%) and Indian (74%) children.  Children responding to oral steroids were not biopsied. 
As previous studies identified NPHS2 autosomal recessive mutations as a major cause of 
familial SRNS in children, we sequenced NPHS2 exons in SSNS and SRNS cases and controls. 
Supplementary Table 1 lists the NPHS2 variants identified in Indian and Black cases and 
controls.  We observed seven missense variants: P20L, G42R, A61V, R229Q, A242V, and 
V260E, all of which have been previously reported, and a novel variant, P369S, which has not 
been reported in the 1000 genomes database or other public databases and is predicted to be 
benign.  NPHS2 V260E (Hg19 coordinate,1:179523626 A/T) is a known pathogenic mutation in 
the homozygous state previously observed in several families from regions of the former Omni 
empire.11 The NPHS2 V260E mutation disrupts podocin trafficking to the podcyte plasma 
membrane by producing a protein that is retained in the endoplasmic reticulum.19NPHS2 R229Q 
is a known pathogenic polymorphism for FSGS, but only in compound heterozygosity with 
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certain other NPHS2 pathogenic mutations in trans conFigureuration.29Other than NPHS2 
V260E, no missense variants were observed in the homozygous or compound heterozygous 
state in Black or Indian SSNS or SRNS cases. NPHS2 mutations in the heterozygous state are 
not predicted to cause disease, and gene burden tests for these variants did not reveal an 
excess of variants in SSNS or SRNS cases versus controls (p>0·5).  
 Notably, the NPHS2 V260E mutation was present in the homozygous state in 8 of 30 (27%) 
Black SRNS cases; V260E homozygosity was specifically associated with biopsy-confirmed 
FSGS (Table 2.2), accounting for 33% of children (8/24) with SR-FSGS.  NPHS2 V260E 
homozygosity was observed only among Black children with SRNS.  One Black child in the 
control group was heterozygous for NPHS2 V260E; the variant was not observed in any of the 
Indian NS cases or controls (Tables 2.2 and 2.3).  
To replicate the 260E/E association with SR-FSGS, we sequenced DNA from a second group of 
20 unrelated Black children with SR-FSGS, and 18 race-and age-matched controls.  Of the 
children with SR-FSGS, 6/20 (30%) were homozygous for V260E whereas none of the controls 
in this cohort carried the mutation. Combining the discovery and replication SR-FSGS cases, 
V260E homozygosity accounted for 14/44 (32%) of Black children with SR-FSGS, P<10-6. 
(Table 2.3). Black SR-FSGS cases homozygous for V260E had an earlier age of onset 
compared to SRNS cases homozygous for the V260 allele (median age 34 months versus 78 
months, respectively, p=0·009) (Figure 2.1). The deleterious mutation was found in the 
heterozygote state in 1/73 discovery and replication controls, for a nominal observed population 
allele frequency of 0·7%, (95% binomial CI: 0·02%, 4%) (Table 2.3) indicating that this variant is 
modestly rare in this southern African population. The ExAC Browser (exac.broadinstitute.org) 
reports a population frequency of 0.0001926 (<1/10,000) in Africans and 0 in Asians, 
Europeans, Latinos, and South Asians. 
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2.4.1 Response to therapy 
We measured response to therapy by urinary protein-creatinine ratio (uPCR) and serum 
albumin levels in children with SRNS. No subjects homozygous for V260 E (N = 14) had either 
full or partial response to additional immunosuppressive therapy (Table 2.4). In contrast, among 
the 32 subjects homozygous for the V260 reference allele, 9 had complete remission, 6 had 
partial remission, and 17 had no treatment response.  Six children carrying 260E/E were further 
treated with tacrolimus (n=3) or intravenous cyclophosomine (n=3), but none showed complete 
or partial remission.  The differences in treatment response between NPHS2 260 EE and 
260VV were statistically significant for complete remission (p=0.04) and combined complete and 
partial remission, p=0.002. 
Eight Black children, all with FSGS and five of whom were homozygous for NPHS2 V260E, 
progressed to end stage kidney disease (eGFR<15 mL/min/1·73m2).   
2.4.2 Founder effect and age of variant 
The association of NPHS2 V260E with familial SR-FSGS suggested that our subjects might 
have cryptic consanguinity by descent from a recent common ancestor. Inbreeding coefficient 
tests implemented in PLINK showed no evidence of very recent genetic relatedness among the 
nine children; however, we considered that a moderately recent founder effect would cause a 
smaller degree of consanguinity that would be revealed by extended regions of homozygosity 
surrounding NPHS2. We determined extent of homozygosity by genotyping 9 individuals –all of 
the individuals with sufficient DNA remaining—carrying two copies of NPHS2 V260E, and 71 
individual lacking the mutation, using the Illumina Exome array, which provides good coverage 
of this region. Two of the 9 V260E homozygous children had stretches of homozygosity around 
NPHS2 of 13 and 14 Mb, with the 7 remaining ranging from 1·9 to 3·6 Mb.  Comparing all of 
these lengths with simulated lengths of homozygosity resulting from recombination over the 
number of generations since the common ancestor indicated that the time to a common 
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ancestor was unlikely to be less than 14 generations (p < 0·.05).  However, it is likely that the 
longer lengths of homozygosity are due to a more recent common ancestor of the parents of 
these children, and that the shorter lengths of homozygosity are more indicative of the time to 
the overall common ancestor; analysis limited to these individuals yielded 31 generations as the 
most likely number of generations since the overall common ancestor, 95% CI 19,47.  
We also tested for association between APOL1 and NS. No Indian cases or controls carried 
either the G1 or G2 variant.  Among the Black controls, the allele frequencies for the G1 and G2 
alleles were 8·9% and 10·1%, respectively. The APOL1 association is largely recessive, with 
carriage of two risk alleles (G1/G2, G1/G1, and G1/G2) required for APOL1-associated FSGS.  
Limiting analysis to individuals not carrying two copies of NPHS2 V260E, 2 of 73 controls and 1 
of 30 FSGS cases carried two APOL1 risk alleles, OR = 1·2, (95% CI 0·02, 24·3), p = 1, 





We have shown that one pathogenic recessive mutation, NPHS2 V260E, accounted for 27% of 
SRNS and 32% of SR-FSGS among unrelated Black children presenting with NS. This was an 
unexpected result since published data suggest that NPHS2 mutations are identified in <15% of 
children with sporadic FSGS and rarely in black children; further, it was unexpected that a single 
variant would account for approximately 30% of SR-FSGS.15,16 Children homozygous for 
NPHS2 V260E were steroid resistant with FSGS, did not respond to intensive treatment, and 
developed disease at a younger age compared to non-carriers, consistent with the severity of 
disease previously reported for the NPHS2 V260E pathogenic mutation.11NPHS2 V260E, like 
the European founder mutation, NPHS2 R138Q, disrupts the trafficking of the altered podocin 
protein to the plasma membrane by its retention in the endoplasmic reticulum. Nephron 
localization is essential for recruitment of nephrin to lipid rafts and structural integrity of the 
podocyte slit diaphragm.18,19 
To elucidate the history of this mutation and to determine if consanguinity accounted for the high 
rate of V260E homozygosity, we genotyped 9 subjects, those with sufficient remaining DNA and 
homozygous for V260E, and 71 Black cases and controls without the mutation, with a genome-
wide array. Overall, parents of children carrying the V260E mutation showed no sign of recent 
consanguinity, but rather showed evidence, in the length of extended homozygous segments 
around NPHS2, of descent from a common ancestor 31 generations removed from the present, 
indicating that the high frequency of this variant in SR-FSGS is not due to a recent common 
ancestor, and suggesting a moderately rare but widespread presence on chromosomes among 
the Black Zulu population. 
V260E resembles the founder nonsense mutation NPHS2 R138X, which was identified in SRNS 
patients from two consanguineous kindreds of Israeli-Arab origin. The mutation was also found 
in 6/18 children from unrelated, but highly inbred families, all of whom shared the same 
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haplotype.30  However, unlike Israeli-Arabs in the prior study, consanguineous relationships are 
uncommon among Zulu and the affected children did not share haplotypes from a recent 
common ancestor. These studies, and others, affirm the importance of sequencing efforts to 
detect disease-causing founder variants that may account for population-specific disparities in 
disease prevalence, presentation, or treatment response. 
Previous observations of SRNS caused by NPHS2 V260E have been in families from regions 
where consanguineous marriage is practiced (i.e., Southwest Asia, Saudia Arabia or the Indian 
Ocean islands, with several areas associated with the Omani empire of the late 17th to 19th 
centuries, prompting the hypothesis that the mutation spread with travel and migrations 
associated with this empire. 11,31 The Omani empire was a power on the East African coast from 
the 1690s to the mid-19th century, and in the early 19th century traded extensively with the 
African Great Lakes region, where Bantu ancestors of the Zulu population lived.32 However, the 
age of the mutation in the studied population suggests an appearance prior to this time and 
makes it more likely that it was introduced by Africans to the Omani Empire. However, it 
remains to be determined whether NPHS2 V260E in our population is related to previously 
observed V260E, or is an independent mutation.  
Our study is limited in that the number of individuals is small, and the results for the studied 
population, Black Africans of the Zulu ethnic group of the KwaZulu-Natal Province, may not be 
generalizable to other Black ethnic groups.  However, the frequency of the association in our 
study, and the age of the mutation, suggest that the mutation may be present in a broader 
population that share ancestry with Zulu, a population of over 20 million.  
Screening for the NPHS2 V260E mutation has the potential to inform the differential diagnosis, 
prognosis, and treatment in Black African children presenting with NS. Identification of this 
mutation as a part of differential diagnosis would be a cost-effective alternative to kidney biopsy 
53 
 
in homozygous carriers, and would identify a large subset of patients who are unresponsive to 
immunosuppressive agents (specifically, oral steroid treatment and cyclophosphamide). This 
would spare children with NPHS2 V260E homozygosity the potentially severe adverse effects of 
toxic agents while at the same time reducing health care costs for an overburdened health care 
system (Figure 2.2). In view of the poor response to immunosuppressive treatment in patients 
with V260E homozygosity, this group of patients should have maximal renoprotection using 
angiotensin converting enzyme inhibitors or angiotensin II receptor blockers. Clinical trials will 
be necessary to determine optimal treatment for homozygous carriers of NPHS2 V260E and 
particularly responsiveness to treatment with non-glucocorticoid immunosuppressive agents.  
 
2.6 Conclusion 
In summary, the high frequency of NPHS2 V260E homozygosity among unrelated children with 
sporadic SRNS makes genetic testing for this mutation in Black African children presenting with 
NS a potential application of precision medicine: for subjects carrying two copies of NPHS2 
V260E a simple genetic test replaces a stressful kidney biopsy and a potentially toxic course of 
treatment. The applicability of this approach may extend beyond the 20 million Zulu living in 
southern Africa, as the variant is likely to be present in other Bantu populations sharing ancestry 
with the. Further studies are vital to define the extent of NPHS2 V260E in children with SRNS, 
and other kidney diseases, in this and related Black African populations. 
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median  age 
34.1 months 




Figure 2.1. Comparison of distributions of ages of onset of steroid resistant nephrotic 
syndrome (SRNS) between carriers of two copies of the reference allele (N = 37) and carriers 
of two copies of the mutant allele (N = 14) at NPHS2 V260E; p value from the Mann-Whitney 
test.  There were no heterozygotes for this locus in the SRNS group. Data are from the 


































Table 2.1. Demographic and clinical characteristics of children with nephrotic syndrome in the discovery 
and replication cohorts. 











    N=31 (%) 
Statistics: 




Steroid sensitive nephrotic syndrome  14 (42·4) 1 (3·2) 
OR 21 (2·8, 960)) 
p = 0·0002 
0 
Steroid resistant nephrotic syndrome 19 (57·6) 30(96·8) 20 
         Age range (months) 37-169 24-168 
p = 0·34 
 
11-149 
         Median age (months) 86 83 97 
         Males 13 (31·6) 13 (43·3) 
2·8 (0·7, 11·5) 
p=0·14 
13 (62%) 
         Females 6 (68·4) 17 (56·7) 7 (38%) 
Histology of steroid resistant nephrotic syndrome 




   Interstitial nephritis 1 (5·3) 2  (6·7) ND 0 
   Mesangioproliferative 
glomerulonephritis  
1 (5·3) 2  (6·7) ND 0 
   Mesangial sclerosis 0 1 (3·3) ND 0 
   Proliferative glomerulonephritis 0 1 (3·3) ND 0 
64 
 
   Glomerulonephritis 2 (10·5) 0 ND 0 
   Minimal change disease 1 (5·3) 0 ND 0 
Shown are the numbers (percent) of steroid sensitive (SSNS) and steroid resistant nephrotic syndrome (SRNS). 








Table 2.2. NPHS2 V260E in Black and Indian SSNS and SRNS with 
nephrotic syndrome in the discovery cohort. 
 













Steroid sensitive NS 1 0 14 0 
Steroid resistant NS1 22  8 19 0 
     FSGS  16 (73%) 8  (100%) 14 (74%) 0 
     Other histologies  6 (27%) 0 5 (26%) 0 
 
1 Only children who showed no remission in proteinuria after a 4 week course of 
corticosteroid treatment underwent renal biopsy. Shown are the number of NPHS2 
V260E genotypes in the nephrotic syndrome discovery cohort. No steroid sensitive 
case carried the NPHS2 260E mutation and the mutation was not observed in 




Table 2.3 Association of NPHS2 V260E restricted to the subset of Black 
children with steroid resistant FSGS from the discovery (n=24) and 











OR (95%CI), PFET 
p. 260 V/V 54 (98%) 16 (67%) Reference 
p. 260 E/V 1   (2%) 0 Not significant 
p. 260 E/E 0 8 (33%) 
Infinite (4·9, infinite) 
3 x 10-5 
Replication cohort 
 
p. 260 V/V  18 (100%) 14 (70%) Reference 
p. 260 V/E 0 0 -- 
p. 260 E/E 0 6 (30%) 




p. 260 V/V 72 (99%) 30 (68%) Reference 
p. 260 V/E 1 (1%) 0 Not significant 
p. 260 E/E 0 14 (32%) 
Infinite (7·2, Infinite) 
3 x 10-7 
NPHS2 genotypes are summarized for individuals with SR-FSGS and controls. 
NPHS2 sequencing results were available for 44 FSGS cases and 73 controls.  






























Table 2.4:  Response to therapy by NPHS2 genotype 
for all black NS cases. 
 













p. 260 VV 17 (53) 6 (19) 9 (28) 15 (47) 
p. 260 EE 14 (100) 0 0 0 
 P value  0·16 0·04 0·002 
 
In contrast to patients with NPHS2 260 V/V, patients with NPHS2 E/E 
showed no response to standard or extensive treatment.  Complete 
remission was defined as urine protein/creatinine ratio (PCR) < 0·2g/mmol 
and serum albumin > 30g/dL. Partial remission was defined as not meeting 
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Sequencing and genotyping 
Exons 1 through 8 were sequenced using ABI Prism BigDye Terminator on the ABI 3700 
Analyzer at standard conditions using primers from Boute et al. for exons 2-7.1 A new primer 
was designed within genomic regions flanking NPHS2 exon 1 
(TGTAAAACGACGGCCAGTCGACTCCACAGGGACTGC  -NPHS2_ex1_Forward) and 
(CAGGAAACAGCTATGACC CCTTAGTTACCACCTGGA - NPHS2_ex1_Reverse). M13F 
(TGTAAAACGACGGCCAGT) and M13R (CAGGAAACAGCTATGACC) sequence tags were 
added to the primers to aid in sequencing.  Exon 1 fragments were amplified using a TaKaRa 
LA Taq kit (CloneTech, Mountain View, CA), using GC Buffer I according to the manufacturer’s 
suggestion. PCR conditions were the following: 94 C for 1 minute followed by 30 cycles of 94 C 
for 1 minute; 57 C for 2 minutes 30 sec, followed by an extension at 72o C for 10 minutes. For a 
coalescence analysis to determine the age of the variants we genotyped DNA from 9 V260E 
homozygous patients and 71 individuals who did not carry the mutation, using the Human 










Bioinformatics Methods  
Estimating time since the most recent common ancestor:  Supplemental Figures 1 and 2 
plot homozygous (top line) and heterozygous (bottom line) SNPs genotyped on the Illumina 
Exome chip, vs. genomic position relative to NPHS2 V260E, for a region of 10 million base pairs 
on either side of the locus. Figure S1 plots data for 9 individuals homozygous for the E (risk) 
allele, while Figure S2 plots data for individuals homozygous for the V (common) allele.  The 
one (control) subject heterozygous for the mutation did not have DNA available for the exome 
chip.  Figure S3 shows histograms of the length of homozygosity around V260E for individuals 
carrying (top) and lacking (bottom) the mutation.  Overall the lengths of homozygosity are much 
longer for individuals carrying the mutation, indicating sequence identity for these individuals for 
the chromosomal region around V260E inherited from the individual’s two parents, which 
indicates a lack of recombination in either chromosome, over this region, since the most recent 
common ancestor of the individual’s parents carrying the mutation.2,3We wish to test the 
hypothesis that there is a recent common ancestor for all the copies of the mutation carried by 
the subjects; the number of generations since this ancestor must be at least as long as the 
maximum of the number of generations since the common ancestor of the two parents, over all 
of the individuals.  A direct coalescence determination of the time to a single common ancestor 
would require the actual haplotypes for this region for all individuals, which we have not 
determined.   
Simulation program for modeling length of homozygosity:  To estimate the time to a 
common ancestor for pairs of parents, we performed a coalescent simulation, simulating 
recombination in succeeding generations following the putative common ancestor. We assume 
that recombinations occur as a Poisson process at the rate of 1/100mB/generation; 
recombination data from deCODE indicates genome average rates of recombination in the 
region around NPHS2 (0.99 and 0.73 centimorgan per megabase for females and males, 
71 
 
respectively),4 and on scales greater than 3 Mb African and European recombination rates are 
essentially identical.5 We model a length of chromosome extending in each direction from the 
center (V260E in NPHS2), with initial length 100mB.  For each recombination that shortens the 
segment, the new length is recorded.  The model tracks two chromosomes, each descending 
from the common ancestor, for n generations, then assumes that an individual has inherited one 
copy of each.  On each side of the mutation the length of homozygosity—length of shared 
chromosome—will be the minimum of the lengths of the unrecombined chromosomes.  The sum 
of these is the length of homozygosity.   
 We simulated this process for numbers of generations running from 6 to 48.  We assume 
that the two chromosomes inherited by the proband are the same number of generations 
removed from the common ancestor; a small deviation from this will not significantly affect the 
simulation results. For each number of generations we ran 100,000 simulations.   
 The simulation assumes that the proband’s parents have no common ancestors more 
recent than the assumed founder of the mutation in the population.  Having more recent 
common ancestors can result in longer segments of homozygosity; if the overall common 
ancestor is many generations removed in time, we would expect that some individuals’ parents 
would have more recent common ancestors.  Among the 9 individuals carrying two copies of 
V260E AA, two had distinctly longer segments of homozygosity (Figureure S3), suggesting a 
more recent ancestor.   
 We estimate the time to the overall common ancestor by comparing the observed 
lengths of homozygosity with the simulation predicted lengths, for the simulated range of 
number of generations, with a Wilcox rank test.  Using all 10 individuals, the rank test indicates 
that the number of generations is unlikely to be less than 14 (p < 0.05), with the most likely 
number of generations being 23.  Assuming the two individuals with longer homozygosity to 
72 
 
have more recent common ancestry than the overall, which is more plausible, the number of 








Figure S1:  Heterozygous and homozygous loci around NPHS2 V260E from genotyping 
by the Illumina Exome V2.1 chip, for nine individuals carrying p.260 E/E (homozygous for 
the variant allele).  The region shown is 10 mB before and after V260E; x axis coordinates 
are base positions relative to this locus.  Top dots represent homozygous loci, bottom 
heterozygous; the region lacking heterozygous loci indicates the region where the 








Figure S2:  Heterozygous and homozygous loci around NPHS2 V260E from genotyping by the Illumina Exome V2.1 chip, for 40 individuals 
(representative of 71 total) carrying  p.260 V/V (homozygous for the wild type allele), for comparison with Figureure S1.  In contrast to the 




Figure S3:  Histograms of the extent of homozygosity around NPHS2 V260E, for individuals homozygous for the mutant allele, and for 
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Supplementary Table 1:  NPHS variants detected in Indian and Black African children with nephrotic syndrome, and controls. 
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  No 1 
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P369S 
c.1105C>T 0 0 0 0 1 
2% 
0 0 0 0 0 This study Tolerated Benign No This 
study 













0 7 (50) 0 17 (56·7) 48 (65·8) 
1 5 (35·7) 0 12 (40) 23 (31·5) 
2 2 (14·2) 0 1    (3·3)   2  (2·7) 
 
1One control was heterozygous for NPHS2 V260E; Because NPHS2 E/E genotype is 
completely penetrant, the association of APOL1 variants with FSGS is restricted to those 
with the reference genotype (NPHS2 V/V). OR 1.2 (95%CI: 0·2, 24·3), P (FET)=1, for 
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INFORMED CONSENT FOR PATIENTS WITH STEROID RESISTANT NEPROTIC 
SYNDROME 
INFORMATION GIVEN TO PARTICIPANTS:  
 
Your child has a kidney disease because he/she is losing protein through the kidneys, 
which is also causing swelling of the body.  This disease is called ‘Nephrotic 
Syndrome’.  We use steroids to treat this disease but some children become resistant 
to steroids and may subsequently develop chronic kidney failure.  Previous studies 
have shown changes in certain genes leading to the development of steroid resistant 
nephrotic syndrome. 
 
To date there have been no studies in Africa on the genetic aspects of steroid 
resistant nephrotic syndrome.  In this study we want to find what changes occur in 
these genes that lead to the development of steroid resistant nephrotic syndrome.     
 
This study will take place at King Edward VIII Hospital (KEH VIII) and Inkosi Albert 
Luthuli Central Hospital (IALCH).  Professor Adhikari, Professor Bhimma, Dr Richard 
Naidoo, and Ms Kareshma Asharam will conduct the study.  The aim of this study is to 
determine the genetic basis of steroid resistant nephrotic syndrome (SRNS) in black-
African and Indian children. 
 
To conduct this study we require a kidney biopsy sample and blood samples from 
your child for genetic analysis.  You will be given a detailed explanation of how a 
kidney biopsy is done and the risks involved before you sign consent for the 






For further enquiries please contact 
Prof R Bhimma   - Tel.:  031-2604351  or   
Ms Kareshma Asharam  - Tel.:   031-2604489 
 
Your participation in this study will not alter the management of your child’s disease 
and no experimental treatment will be used.  You can withdraw from the study at any 




You will be given a signed and dated copy of this consent form. 
SIGNATURES 
I agree to let my child’s doctor use and give out my child’s health information in the way it is 
described in this consent form until the end of the research study. 
I have read this consent form, and I agree for my child ______________________to take 
part in this study as it is explained in this consent form. 
_            ____ 
Date                                                 Signature of Parent (s) or Surrogates (s)  
 
I give my permission to have some of the samples of my child’s blood and kidney biopsy 
specimen frozen and stored for possible future testing, as discussed.  
 
_______________________ _____________________________ 
 Date   Signature of Parent 
I certify that I have explained the above to ______________________________ and believe 
that the signature(s) was affixed freely.  I also agree to answer any questions that may arise.
    
________________________ ______________________________ 
Date                          Signature of P.I. or person presenting  
Printed Name of Person Providing Oral Translation:      
Relationship of Translator to Subject, Parent, or Surrogate:      





I have read this assent form, and I ____________________________agree to take part in 
this study as it is explained in this assent form. 
____________   __________________________ 
Date                                             Signature of Child (only those 8-17 years old) 
I give my permission to have a sample of my blood and kidney tissue frozen and stored for 
possible future testing, as discussed.  
____________   __________________________ 
Date                                             Signature of Child (only those 8-17 years old) 
Please indicate how assent was obtained by initialling the applicable line:   
I certify that I have explained the above to ____________________________ and believe 
that the signature was affixed freely.  I also agree to answer any questions that may arise. 
Written assent was not obtainable because ____________________________.  However, I 
certify that I have explained the above to ___________________________________ and 
believe that verbal assent was freely given.  I also agree to answer any questions that may 
arise. 
_____________       ___________________________________   
Date Signature of the Principal Investigator 
or person presenting information 







INFORMED CONSENT FOR PATIENTS WITH STEROID SENSITIVE NEPHROTIC 
SYNDROME 
 
INFORMATION GIVEN TO PARTICIPANTS:  
 
Your child has a kidney disease ‘Nephrotic Syndrome’.  We use steroids to treat this 
disease and your child has responded to this treatment.  However some children 
become resistant to steroids and may subsequently develop chronic kidney failure.  
Previous studies have shown changes in certain genes leading to the development of 
steroid resistant nephrotic syndrome. 
 
To date there have been no studies in Africa on the genetic aspects of steroid 
resistant nephrotic syndrome.  In this study we want to find what changes occur in 
these genes that lead to the development of steroid resistant nephrotic syndrome.     
 
This study will take place at King Edward VIII Hospital (KEH VIII) and Inkosi Albert 
Luthuli Central Hospital (IALCH).  Professor Adhikari, Professor Bhimma, and Ms 
Kareshma Asharam will conduct the study.  The aim of this study is to determine the 
genetic basis of steroid resistant nephrotic syndrome (SRNS) in black-African and 
Indian children. 
 
To conduct this study we require a 5mls (1 teaspoon) of blood samples from your 
child for genetic analysis.  The bloods will be taken once off, a study number will be 
assigned to the sample.  Part of the sample will be used for further genetic testing 
when required. You will be made aware of the results as soon as all data is collated 





For further enquiries please contact 
Prof R Bhimma   - Tel.:  031-2604351  or   
Ms Kareshma Asharam  - Tel.:   031-2604489 
Your participation in this study will not alter the management of your child’s disease 
and no experimental treatment will be used.  You can withdraw from the study at any 




You will be given a signed and dated copy of this consent form. 
SIGNATURES 
I agree to let my child’s doctor use and give out my child’s health information in the way it is 
described in this consent form until the end of the research study. 
I have read this consent form, and I agree for my child ______________________to take 
part in this study as it is explained in this consent form. 
 
_            ____ 
Date                                                 Signature of Parent (s) or Surrogates (s)  
 
I give my permission to have some of the samples of my child’s blood and kidney biopsy 
specimen frozen and stored for possible future testing, as discussed.  
_______________________ _____________________________ 
 Date   Signature of Parent 
I certify that I have explained the above to ______________________________ and believe 
that the signature(s) was affixed freely.  I also agree to answer any questions that may arise.
    
________________________ ______________________________ 
Date                                      Signature of P.I. or person presenting                                                           
. 
Printed Name of Person Providing Oral Translation:      




You will be given a signed and dated copy of this assent form. 
SIGNATURES 
I have read this assent form, and I ____________________________agree to take part in 
this study as it is explained in this assent form. 
____________   __________________________ 
Date                                             Signature of Child (only those 8-17 years old) 
I give my permission to have a sample of my blood and kidney tissue frozen and stored for 
possible future testing, as discussed.  
____________   __________________________ 
Date                                             Signature of Child (only those 8-17 years old) 
Please indicate how assent was obtained by initialling the applicable line:   
I certify that I have explained the above to ____________________________ and believe 
that the signature was affixed freely.  I also agree to answer any questions that may arise. 
Written assent was not obtainable because ____________________________.  However, I 
certify that I have explained the above to ___________________________________ and 
believe that verbal assent was freely given.  I also agree to answer any questions that may 
arise. 
______________       ___________________________________   
Date Signature of the Principal Investigator 







Typed Name of Principal Investigator 
or person presenting information 
 
Verbal assent could not be obtained because 
_________________________________________________________________________ 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________. 
 
